NCOA3 and neoplasm: Since Tregs are known to normally repress the immune system’s tumor-attacking conventional T cells (Tcons), we hypothesized that our drug (SI-2) might inhibit SRC-3 in Tregs and derepress Tcons so they can attack tumors.